Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
In an oversubscribed round, top-tier investors provide significant financial resources to accelerate clinical development of potentially best-in-class therapies for inflammatory/autoimmune diseases
SAN DIEGO and TAICANG, SUZHOU, China, Aug. 24, 2020 -- ... Biopharmaceuticals, Venture Capital, Personnel Connect Biopharma, atopic dermatitis, ulcerative colitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | China Health | Clinical Trials | Dermatitis | Dermatology | Inflammatory Bowel Disease | Pharmaceuticals | Ulcerative Colitis | Venture Capital